Display options
Cite
King KM, Lupichuk S, Baig L, et al. Optimal use of taxanes in metastatic breast cancer. Curr Oncol. 2009;16(3):8-20doi: 10.3747/co.v16i3.377.
King, K. M., Lupichuk, S., Baig, L., Webster, M., Basi, S., Whyte, D., & Rix, S. (2009). Optimal use of taxanes in metastatic breast cancer. Current oncology (Toronto, Ont.), 16(3), 8-20. https://doi.org/10.3747/co.v16i3.377
King, K M, et al. "Optimal use of taxanes in metastatic breast cancer." Current oncology (Toronto, Ont.) vol. 16,3 (2009): 8-20. doi: https://doi.org/10.3747/co.v16i3.377
King KM, Lupichuk S, Baig L, Webster M, Basi S, Whyte D, Rix S. Optimal use of taxanes in metastatic breast cancer. Curr Oncol. 2009 May;16(3):8-20. doi: 10.3747/co.v16i3.377. PMID: 19526080; PMCID: PMC2695713.
Copy Download .nbib Format: NLM
Share it on

Curr Oncol. 2009 May;16(3):8-20. doi: 10.3747/co.v16i3.377.

Optimal use of taxanes in metastatic breast cancer.

Current oncology (Toronto, Ont.)

K M King, S Lupichuk, L Baig, M Webster, S Basi, D Whyte, S Rix

Affiliations

  1. Cross Cancer Institute, Edmonton, AB. [email protected]

PMID: 19526080 PMCID: PMC2695713 DOI: 10.3747/co.v16i3.377

Abstract

The role of taxanes in the treatment of breast cancer is becoming increasingly important. In clinical practice, the taxanes are now standard therapy in both early-stage and metastatic breast cancer. Since the 1990s, multiple randomized clinical trials have been evaluating the efficacy of taxanes in the treatment of metastatic breast cancer. These trials have included treatment with taxanes alone or in combination with other chemotherapeutic agents. Pre-existing published guidelines for the use of taxanes in the management of metastatic breast cancer are available. The mandate of the Alberta Cancer Board Provincial Breast Tumour Group Guideline Panel was to consider and adapt the recommendations of the existing guidelines and to develop de novo guidelines to account for current evidence. For this task, the panel used the ADAPTE process, which is a systematic process of guideline adaptation developed by the ADAPTE Collaboration.The recommendations formulated by the panel included the identification of taxane regimens that could be offered in anthracycline-naïve patients, anthracycline-pretreated or -resistant patients, and patients overexpressing the human epidermal growth factor receptor 2. Potential toxicities and benefits in terms of time to progression, progression-free survival, overall survival, and quality of life were also considered.

Keywords: Metastatic breast cancer; chemotherapy; docetaxel; nab-paclitaxel; paclitaxel

References

  1. Eur J Cancer. 2006 Aug;42(12):1797-806 - PubMed
  2. J Clin Oncol. 1999 May;17(5):1413-24 - PubMed
  3. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD003366 - PubMed
  4. Semin Oncol. 1995 Aug;22(4 Suppl 8):33-9 - PubMed
  5. J Clin Oncol. 2004 Jul 1;22(13):2587-93 - PubMed
  6. J Clin Oncol. 2005 Nov 1;23(31):7794-803 - PubMed
  7. J Clin Oncol. 1995 Feb;13(2):502-12 - PubMed
  8. N Engl J Med. 2008 Apr 17;358(16):1663-71 - PubMed
  9. J Clin Oncol. 2008 Apr 20;26(12):1980-6 - PubMed
  10. Br J Cancer. 2002 May 6;86(9):1367-72 - PubMed
  11. J Clin Oncol. 2008 Apr 1;26(10):1642-9 - PubMed
  12. J Clin Oncol. 2002 Jun 15;20(12):2812-23 - PubMed
  13. Cancer. 2004 Aug 15;101(4):704-12 - PubMed
  14. J Clin Oncol. 2006 Jun 20;24(18):2786-92 - PubMed
  15. J Clin Oncol. 2009 Apr 10;27(11):1753-60 - PubMed
  16. J Clin Oncol. 2005 Aug 20;23(24):5542-51 - PubMed
  17. J Clin Oncol. 2003 Feb 15;21(4):588-92 - PubMed
  18. Ann Oncol. 2004 Sep;15(9):1358-65 - PubMed
  19. Breast Cancer Res Treat. 2007 Mar;101(3):355-65 - PubMed
  20. J Clin Oncol. 2005 Sep 1;23(25):5983-92 - PubMed
  21. Breast Cancer Res Treat. 2008 May;109(2):343-50 - PubMed
  22. J Clin Oncol. 2005 Jul 1;23(19):4265-74 - PubMed
  23. Ann Oncol. 2007 Feb;18(2):215-25 - PubMed
  24. J Clin Oncol. 1999 Aug;17(8):2341-54 - PubMed
  25. Gynecol Oncol. 2007 Jul;106(1):181-92 - PubMed
  26. Eur J Cancer. 1999 Aug;35(8):1194-201 - PubMed
  27. J Clin Oncol. 2000 Feb;18(4):724-33 - PubMed
  28. N Engl J Med. 2001 Mar 15;344(11):783-92 - PubMed

Publication Types